Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

  • Axel Hauschild
  • , Sanjiv S. Agarwala
  • , Uwe Trefzer
  • , David Hogg
  • , Caroline Robert
  • , Peter Hersey
  • , Alexander Eggermont
  • , Stephan Grabbe
  • , Rene Gonzalez
  • , Jens Gille
  • , Christian Peschel
  • , Dirk Schadendorf
  • , Claus Garbe
  • , Steven O'Day
  • , Adil Daud
  • , J. Michael White
  • , Chenghua Xia
  • , Kiran Patel
  • , John M. Kirkwood
  • , Ulrich Keilholz

Research output: Contribution to journal › Article › peer-review

495 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science